model updat ahead
preced mdt fy earn releas updat fy
sales/ep estim cc report exhibit
cc estim compar
consensu manag sale growth
rang cc ep rang forecast gm/
om excl /om incl /tax vs prior
updat fy estim updat fy sales/ep
estim cc report exhibit
cc vs consensu
 in-lin compani sale growth guidanc
cc report impli ep rang
incl fx acknowledg revenu basi
slightli revis januari guid toward middl
cc revenu growth rang note oper margin excl
optic appear grow versu promis
oper howev underli progress obscur fx forecast
gm/om excl /om incl /tax vs prior
chang larg driven decreas
cardiac rhythm heart failur coronari structur heart
slightli off-set higher spine specialti therapi
thesi valuat risk continu see upsid share price
given view like enjoy organ msd sale growth
compound-annual-growth-rate margin expans per year share buyback
drive hsd ep growth compound-annual-growth-rate given increas cash
access accru recent enact us tax reform increas
focu free cash flow convers peer group averag
hope aggress vis-a-vi high growth
earlier stage acquisit could add spice stori given mdt
unquestion strength clinic trial regulatori commerci execut
compani diversif size tend obscur
particip high growth med-tech segment tavr
stand-alone cgm endo-ven renal denerv offset
price pressur matur declin market innov micra
procedur optim mazor/o-arm/stealth spinal fusion also like
tr target
mdt recent recommit re-messag back innovation-centr root alter
manag incent highlight margin free cash flow expans well establish
emerg market presenc target valu base initi inclus tyrx diabet
outcom risk share unit healthcar buy david macdonald pt base
rel valuat framework regress estim report forward top-line compound-annual-growth-rate
rel forward price-to-earnings med-tech stock incorpor estim mdt
report organ revenu compound-annual-growth-rate framework ascrib rel forward p/
 multipl month averag forward multipl ep month henc
arriv price target risk pt includ emerg market opacity/volatil greater
expect matur product market weak failur meet margin expans expect
updat guidance/revenu expect mazor robot acquisit close decemb
detail breakdown new robot placement capit sale volume-bas
contract earli feedback mazor stealth launch launch end-januari diabet
segment updat includ progress guardian connect cgm launch intern expans
minim thought potenti chang apollo trial given coapt result
present tct share underli tavr market momentum like impact favor
low risk trial result present march perceiv competit
buy portfolio highlight addit studies/tri present
includ result wrap-it believ potenti chang standard
care guidelin cardiac rhythm implant updat intellis/sc market momentum
timelin launch intern market throughout fy well competit outlook deep
brain sacral nerv feedback earli test surgic robot platform expect
launch fy like impact mitg trajectori updat like impact
announc unfavor one time fy tax hit well currenc headwind
ep growth next fy confid regard near long-term oper margin
expans goal fy
earn call februari et dial-in id
page
exhibit fy revenu varianc vs consensu segment product categori
page
exhibit cont fy revenu varianc vs consensu segment product categori
page
page
incom statementstrh estimatesactualconsensusno ofstrh estimate vs consensu cc incom incl expens ni ex attribut estimatesactualconsensusno ofstrh estimate vs consensusmargin margin incl medtron plc
exhibit fy revenu varianc vs consensu segment product categori
page
exhibit cont fy revenu varianc vs consensu segment product categori
page
page
page
period million oper ens incom excl non-oper net incom ex ni ex attribut analysisgross margin excl margin incl margin excl margin attribut analysi y/i cc pf pmr incom attribut medtron plc
world largest medic devic compani leadership across major market
compani four busi segment cardiac vascular minim invas technolog
restor therapi diabet headquart dublin ireland
continu see upsid share price given view like enjoy organ msd
sale growth compound-annual-growth-rate margin expans per year share buyback
drive hsd ep growth compound-annual-growth-rate given increas cash access accru
recent enact us tax reform increas focu free cash flow convers
peer group averag hope aggress vis-a-vi high growth
earlier stage acquisit could add spice stori given mdt unquestion strength
clinic trial regulatori commerci execut compani diversif size tend
obscur particip high growth med-tech segment tavr tmvr
spinal disc close loop insulin deliveri stand-alone cgm endo-ven renal denerv
offset price pressur matur declin market innov micra procedur
optim mazor/o-arm/stealth spinal fusion also like mdt recent recommit re-
messag back innovation-centr root alter manag incent highlight
margin free cash flow expans well establish emerg market presenc target
valu base initi inclus tyrx diabet outcom risk share unit healthcar
valuat risk
pt base rel valuat framework regress estim report
forward top-line compound-annual-growth-rate rel forward price-to-earnings med-tech stock incorpor
estim mdt report organ revenu compound-annual-growth-rate framework
ascrib rel forward price-to-earnings multipl month averag forward multipl
ep month henc arriv price target risk pt includ emerg
market opacity/volatil greater expect matur product market weak failur meet
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
